Corient Private Wealth
TCON

Corient Private Wealth’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Corient Private Wealth’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,873
Closed -$24.7K – 2409
2024
Q1 		$24.7K Hold
2,873
– – ﹤0.01% 2255
2023
Q4 		$10.1K Hold
2,873
– – ﹤0.01% 2238
2023
Q3 		$10.2K Hold
2,873
– – ﹤0.01% 2122
2023
Q2 		$16.7K Hold
2,873
– – ﹤0.01% 2056
2023
Q1 		$109K Hold
2,873
– – ﹤0.01% 1872
2022
Q4 		$85.6K Buy
+2,873
New +$86.9K ﹤0.01% 1585

Other funds holding TCON

GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return

Corient Private Wealth's TCON Position: Q2 2024 in Review

Corient Private Wealth sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 2,873 shares — an estimated $24.7K sold.

Corient Private Wealth first reported a position in TCON in Q4 2022 and held it in 6 quarters. The position peaked at $109K in Q1 2023. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

  • Corient Private Wealth reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Corient Private Wealth sold 2,873 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $24.7K.
  • Corient Private Wealth first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
  • Corient Private Wealth's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $109K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Corient Private Wealth's 13F filing for Q2 2024, filed 13 Aug 2024.